Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients

President Trump announced a 17th MFN drug-pricing deal, this time with Regeneron, extending lower U.S. prices to Medicaid and TrumpRx patients. Regeneron will cut Praluent from $537 to $225 for direct purchasers, while its new gene therapy Otarmeni will be provided at no cost to U.S. patients under the agreement. The company also committed $27 billion of U.S. R&D and manufacturing investment by 2029, lifting total U.S. pharma investment under Trump to $448 billion.

Analysis

This is a policy shock that changes the pricing power distribution inside large-cap pharma more than it changes the sector’s aggregate earnings. The immediate winners are companies with outsized U.S. mix and already-credible manufacturing footprints, because they can trade pricing concessions for regulatory certainty and volume preservation; the losers are firms that still rely on ex-U.S. price discrimination to subsidize R&D economics. The less obvious effect is on supply-chain capex: onshoring commitments should accelerate demand for fill-finish, biologics CDMOs, and specialty manufacturing equipment even if branded-drug gross margins compress.

The market will likely underprice the duration risk. Near-term, the headline is “deal signed,” but the bigger issue is whether MFN becomes a template for Medicaid, direct-to-consumer channels, and future launches across the class. That creates a multi-quarter overhang on U.S. launch assumptions and could force management teams to prioritize fewer, higher-confidence assets over broad pipeline breadth. In contrast, firms with diversified international revenue and more mature franchises have better ability to absorb a U.S. discount without cutting innovation spend, making relative performance within the sector more important than absolute sector direction.

The contrarian view is that this may be less negative for pharma multiples than first appears. Once pricing is partially de-risked, investors may start focusing on unit growth, manufacturing localization, and reduced policy uncertainty, which can support valuation rerating for the strongest operators. The key variable is whether the government can keep extending the model without provoking litigation, renegotiation, or foreign-payer retaliation; if that happens, the current optimism can fade within 3–6 months. If not, the sector may re-rate from a “policy threat” regime to a “managed pricing” regime, which is structurally better for balance sheets but worse for top-line pricing power.

Key Decisions for Investors

• Long PFE / short XBI for 1–3 months: PFE has the cleanest benefit from reduced policy uncertainty and is best positioned to absorb pricing pressure; XBI remains exposed to pipeline-duration compression if the market starts discounting future launch pricing.
• Pair long NVS or SNY vs short ABBV or GILD over 2–4 months: prefer diversified global revenue streams and lower dependence on a small number of U.S.-sensitive growth drivers; hedge with sector beta to isolate policy dispersion.
• Buy call spreads on life-sciences manufacturing names over 3–6 months (e.g., CDMO/equipment basket): the capex-onshoring implication is second-order but durable, and the market is likely to lag the revenue uplift versus branded pharma headwinds.
• Use any 5–8% sector pullback to add selectively to AMGN/AZN on a 6–12 month horizon: these names can typically defend margins better through mix, scale, and manufacturing control; avoid chasing fresh upside after headline-driven squeezes.
• Avoid outright long-duration exposure to the most U.S.-concentrated branded names until litigation/regulatory scope is clarified; the risk/reward skews worse if MFN expands from launch pricing into broader reimbursement channels.